Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...

Roche’s new TAGS technology overcomes the technical limitations of a typical 4-plex test result in previous solutions, using a novel, proprietary approach. Without having to upgrade hardware or ...

Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo ...

BOSTON -- I can't recall the first time that I met Luis Tiant. But I can tell you that I was in awe when it happened. "El Tiante" was second only to Carl Yastrzemski when it came to Boston Red Sox ...

Le départ du Vendée Globe 2024, a été donné ce dimanche 10 novembre à 13 h 02, aux Sables-d’Olonne. Pour cette dixième édition, 40 skippers sont en lice, un record. Devant une foule ...

Brian Roche co-anchors News 8 at 5 p.m. each weekday. He is also the 8 On Your Side Consumer/Investigative reporter for News 8. Brian is an Emmy Award winning anchor and reporter. He has been ...

1 Day ROG -1.02% DJIA 0.59% S&P 500 0.38% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Speaking to the press Wednesday, Roche’s chief executive Thomas Schinecker critiqued the proposed transaction, arguing that it could hamper the ability of smaller biopharma players to lock down ...

To get from Nice to Port-Fréjus, where Stephen Roche suggests we first meet, the motorway sweeps up and around the Cote d’Azur, bypassing familiar names such as Sainte-Maxime, St-Raphaël ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.